Regencell Bioscience Holdings Ltd Financials
This page shows Regencell Bioscience Holdings Ltd (RGC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Regencell Bioscience Holdings Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Regencell Bioscience Holdings Ltd passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Regencell Bioscience Holdings Ltd reported a net loss of $3.6M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Regencell Bioscience Holdings Ltd's EBITDA was -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.4% from the prior year.
Regencell Bioscience Holdings Ltd reported -$3.6M in net income in fiscal year 2025. This represents an increase of 16.7% from the prior year.
Regencell Bioscience Holdings Ltd earned -$0.72 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Regencell Bioscience Holdings Ltd recorded an outflow of $3.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 18.5% from the prior year.
Regencell Bioscience Holdings Ltd held $2.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Regencell Bioscience Holdings Ltd's ROE was -73.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 21.4 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Regencell Bioscience Holdings Ltd invested $948K in research and development in fiscal year 2025. This represents a decrease of 11.1% from the prior year.
Regencell Bioscience Holdings Ltd invested $153K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 2740.2% from the prior year.
Not reported for fiscal year 2025.
RGC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| R&D Expenses | $948K-11.1% | $1.1M-32.6% | $1.6M-37.0% | $2.5M+473.1% | $438K+13.5% | $386K+69.2% | $228K |
| SG&A Expenses | $2.8M-20.6% | $3.5M-20.0% | $4.4M-12.8% | $5.1M+439.6% | $941K+201.8% | $312K+96.0% | $159K |
| Operating Income | -$3.8M+20.4% | -$4.7M+24.5% | -$6.3M+17.6% | -$7.6M-451.5% | -$1.4M-70.0% | -$812K-107.8% | -$391K |
| Net Income | -$3.6M+16.7% | -$4.3M+26.7% | -$5.9M+21.1% | -$7.4M-452.9% | -$1.3M-65.8% | -$812K-107.8% | -$391K |
| EPS (Diluted) | -$0.72 | -$0.87+26.9% | -$1.19 | -$0.58-346.2% | -$0.13-62.5% | -$0.08 | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, Income Tax.
RGC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Total Assets | $5.8M-31.8% | $8.4M-33.1% | $12.6M-30.0% | $18.0M+5197.6% | $340K-33.8% | $514K | N/A |
| Current Assets | $4.9M-39.6% | $8.1M-30.2% | $11.6M-29.3% | $16.4M+24499.6% | $67K-82.7% | $387K | N/A |
| Cash & Equivalents | $2.4M-18.3% | $3.0M+89.2% | $1.6M-75.6% | $6.4M+10700.7% | $59K-84.6% | $387K+59.0% | $243K |
| Total Liabilities | $895K+307.9% | $220K-65.3% | $632K-32.6% | $938K-78.4% | $4.3M+37.1% | $3.2M | N/A |
| Current Liabilities | $664K+242.8% | $194K-68.1% | $607K+5.0% | $578K-86.7% | $4.3M+37.1% | $3.2M | N/A |
| Total Equity | $4.9M-40.9% | $8.2M-31.7% | $12.0M-29.5% | $17.1M+526.9% | -$4.0M-50.8% | -$2.7M-44.2% | -$1.8M |
| Retained Earnings | -$25.2M-16.6% | -$21.6M-24.8% | -$17.3M-51.3% | -$11.4M-186.2% | -$4.0M-50.8% | -$2.7M | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RGC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.1M+22.2% | -$4.0M+19.4% | -$5.0M+5.8% | -$5.3M-586.4% | -$767K-5.6% | -$727K-85.8% | -$391K |
| Capital Expenditures | $153K+2740.2% | $5K-80.4% | $27K-96.5% | $781K | N/A | $118K | N/A |
| Free Cash Flow | -$3.3M+18.5% | -$4.0M+19.7% | -$5.0M+17.5% | -$6.0M | N/A | -$844K | N/A |
| Investing Cash Flow | $2.7M-48.8% | $5.2M+8789.1% | $59K+100.5% | -$10.8M | N/A | -$118K | N/A |
| Financing Cash Flow | N/A | $102K-24.2% | $135K-99.4% | $22.4M+4995.1% | $440K-55.5% | $988K+105.4% | $481K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RGC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 |
|---|---|---|---|---|---|---|---|
| Return on Equity | -73.8%-21.4pp | -52.3%-3.5pp | -48.8%-5.2pp | -43.6% | N/A | N/A | N/A |
| Return on Assets | -62.3%-11.3pp | -51.0%-4.5pp | -46.5%-5.2pp | -41.3%+354.6pp | -395.9%-237.9pp | -158.0% | N/A |
| Current Ratio | 7.39-34.5x | 41.92+22.8x | 19.15-9.3x | 28.46+28.4x | 0.02-0.1x | 0.12 | N/A |
| Debt-to-Equity | 0.18+0.2x | 0.030.0x | 0.050.0x | 0.06 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Regencell Bioscience Holdings Ltd Ranks
Frequently Asked Questions
Is Regencell Bioscience Holdings Ltd profitable?
No, Regencell Bioscience Holdings Ltd (RGC) reported a net income of -$3.6M in fiscal year 2025.
What is Regencell Bioscience Holdings Ltd's EBITDA?
Regencell Bioscience Holdings Ltd (RGC) had EBITDA of -$3.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Regencell Bioscience Holdings Ltd's return on equity (ROE)?
Regencell Bioscience Holdings Ltd (RGC) has a return on equity of -73.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Regencell Bioscience Holdings Ltd's free cash flow?
Regencell Bioscience Holdings Ltd (RGC) recorded an outflow of $3.3M in free cash flow during fiscal year 2025. This represents a 18.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Regencell Bioscience Holdings Ltd's operating cash flow?
Regencell Bioscience Holdings Ltd (RGC) recorded an outflow of $3.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Regencell Bioscience Holdings Ltd's total assets?
Regencell Bioscience Holdings Ltd (RGC) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Regencell Bioscience Holdings Ltd's capital expenditures?
Regencell Bioscience Holdings Ltd (RGC) invested $153K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Regencell Bioscience Holdings Ltd spend on research and development?
Regencell Bioscience Holdings Ltd (RGC) invested $948K in research and development during fiscal year 2025.
What is Regencell Bioscience Holdings Ltd's current ratio?
Regencell Bioscience Holdings Ltd (RGC) had a current ratio of 7.39 as of fiscal year 2025, which is generally considered healthy.
What is Regencell Bioscience Holdings Ltd's debt-to-equity ratio?
Regencell Bioscience Holdings Ltd (RGC) had a debt-to-equity ratio of 0.18 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regencell Bioscience Holdings Ltd's return on assets (ROA)?
Regencell Bioscience Holdings Ltd (RGC) had a return on assets of -62.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Regencell Bioscience Holdings Ltd's cash runway?
Based on fiscal year 2025 data, Regencell Bioscience Holdings Ltd (RGC) had $2.4M in cash against an annual operating cash burn of $3.1M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Regencell Bioscience Holdings Ltd's Piotroski F-Score?
Regencell Bioscience Holdings Ltd (RGC) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regencell Bioscience Holdings Ltd's earnings high quality?
Regencell Bioscience Holdings Ltd (RGC) reported a net loss of $3.6M while operations used $3.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.